Opus Genetics (IRD) 10-Q 14 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 14, 2020
Document And Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Document Transition Report	false
Entity File Number	001-34079
Entity Registrant Name	REXAHN PHARMACEUTICALS, INC.
Entity Central Index Key	0001228627
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3516358
Entity Address, Address Line One	15245 Shady Grove Road
Entity Address, Address Line Two	Suite 455
Entity Address, City or Town	Rockville
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20850
City Area Code	240
Local Phone Number	268-5300
Title of 12(b) Security	Common Stock, $.0001 par value
Trading Symbol	REXN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		4,234,141

Condensed Balance Sheet

Condensed Balance Sheet - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 9,208,951	$ 9,219,547
Marketable securities		2,997,220
Prepaid expenses and other current assets	817,653	447,206
Total Current Assets	10,026,604	12,663,973
Security Deposits	25,681	25,681
Operating Lease Right-of-Use Assets	139,477	203,348
Equipment, Net	57,312	75,770
Total Assets	10,249,074	12,968,772
Current Liabilities:
Accounts payable and accrued expenses	2,190,753	1,265,731
Deferred revenue	650,000	1,500,000
Operating lease liabilities, current	136,197	139,765
Total Current Liabilities	2,976,950	2,905,496
Operating Lease Liabilities, non-current		63,605
Warrant Liabilities	268,811	41,717
Total Liabilities	3,245,761	3,010,818
Commitments and Contingencies (Note 12)
Stockholders' Equity:
Preferred stock, par value $0.0001, 10,000,000 authorized shares, none issued and outstanding
Common stock, par value $0.0001, 75,000,000 authorized shares, 4,019,141 issued and outstanding	402	402
Additional paid-in capital	173,423,515	173,278,144
Accumulated other comprehensive income		2,084
Accumulated deficit	(166,420,604)	(163,322,676)
Total Stockholders' Equity	7,003,313	9,957,954
Total Liabilities and Stockholders' Equity	$ 10,249,074	$ 12,968,772

Condensed Balance Sheet (Parent

Condensed Balance Sheet (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Condensed Balance Sheet [Abstract]
Preferred Stock, Par Value	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	75,000,000	75,000,000
Common Stock, Shares, Issued	4,019,141	4,019,141
Common Stock, Shares, Outstanding	4,019,141	4,019,141

Condensed Statement Of Operatio

Condensed Statement Of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Condensed Statement Of Operations [Abstract]
Revenues			$ 1,150,000
Expenses:
General and administrative	2,116,891	1,340,016	3,372,898	3,035,538
Research and development	231,607	1,648,401	688,397	3,890,631
Total Expenses	2,348,498	2,988,417	4,061,295	6,926,169
Loss from Operations	(2,348,498)	(2,988,417)	(2,911,295)	(6,926,169)
Other Income
Interest income	6,042	96,650	40,461	178,035
Unrealized (loss) gain on fair value of warrants	(168,702)	427,483	(227,094)	1,940,854
Total Other (Loss) Income	(162,660)	524,133	(186,633)	2,118,889
Net Loss Before Provision for Income Taxes	(2,511,158)	(2,464,284)	(3,097,928)	(4,807,280)
Provision for Income Taxes
Net Loss	$ (2,511,158)	$ (2,464,284)	$ (3,097,928)	$ (4,807,280)
Net loss per share, basic and diluted	$ (0.62)	$ (0.61)	$ (0.77)	$ (1.23)
Weighted average number of shares outstanding, basic and diluted	4,019,141	4,019,141	4,019,141	3,900,208

Condensed Statement Of Comprehe

Condensed Statement Of Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Condensed Statement Of Comprehensive Loss [Abstract]
Net Loss	$ (2,511,158)	$ (2,464,284)	$ (3,097,928)	$ (4,807,280)
Unrealized gain (loss) on available-for-sale securities		19,781	(2,084)	25,015
Comprehensive Loss	$ (2,511,158)	$ (2,444,503)	$ (3,100,012)	$ (4,782,265)

Condensed Statement Of Stockhol

Condensed Statement Of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
Balance at Dec. 31, 2018	$ 312	$ 165,267,656	$ (154,687,242)	$ (17,836)	$ 10,562,890
Balance, shares at Dec. 31, 2018	3,122,843
Issuance of common stock and units, net of issuance costs	$ 90	7,553,738			7,553,828
Issuance of common stock and units, net of issuance costs, Shares	895,834
Common stock issued from vested restricted stock units, shares	464
Stock-based compensation		288,653			288,653
Net Loss			(4,807,280)		(4,807,280)
Other Comprehensive income (loss)				25,015	25,015
Balance at Jun. 30, 2019	$ 402	173,110,047	(159,494,522)	7,179	13,623,106
Balance, shares at Jun. 30, 2019	4,019,141
Balance at Mar. 31, 2019	$ 402	172,982,394	(157,030,238)	(12,602)	15,939,956
Balance, shares at Mar. 31, 2019	4,019,141
Stock-based compensation		127,653			127,653
Net Loss			(2,464,284)		(2,464,284)
Other Comprehensive income (loss)				19,781	19,781
Balance at Jun. 30, 2019	$ 402	173,110,047	(159,494,522)	7,179	13,623,106
Balance, shares at Jun. 30, 2019	4,019,141
Balance at Dec. 31, 2019	$ 402	173,278,144	(163,322,676)	2,084	$ 9,957,954
Balance, shares at Dec. 31, 2019	4,019,141				4,019,141
Stock-based compensation		145,371			$ 145,371
Net Loss			(3,097,928)		(3,097,928)
Other Comprehensive income (loss)				$ (2,084)	(2,084)
Balance at Jun. 30, 2020	$ 402	173,423,515	(166,420,604)		$ 7,003,313
Balance, shares at Jun. 30, 2020	4,019,141				4,019,141
Balance at Mar. 31, 2020	$ 402	173,354,446	(163,909,446)		$ 9,445,402
Balance, shares at Mar. 31, 2020	4,019,141
Stock-based compensation		69,069			69,069
Net Loss			(2,511,158)		(2,511,158)
Balance at Jun. 30, 2020	$ 402	$ 173,423,515	$ (166,420,604)		$ 7,003,313
Balance, shares at Jun. 30, 2020	4,019,141				4,019,141

Condensed Statement Of Cash Flo

Condensed Statement Of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows from Operating Activities:
Net loss	$ (3,097,928)	$ (4,807,280)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	18,458	22,077
Loss on sale of equipment		9,594
Amortization of premiums and discounts on marketable securities, net	(4,864)	(56,019)
Stock-based compensation	145,371	288,653
Unrealized loss (gain) on fair value of warrants	227,094	(1,940,854)
Changes in assets and liabilities:
Prepaid expenses and other assets	(370,447)	22,308
Accounts payable and accrued expenses	925,022	(1,231,816)
Deferred revenue	(850,000)	1,500,000
Other, net	(3,302)	6,706
Net Cash Used in Operating Activities	(3,010,596)	(6,186,631)
Cash Flows from Investing Activities:
Purchase of equipment		(19,383)
Sale of equipment		5,500
Purchase of marketable securities		(8,887,566)
Redemption of marketable securities	3,000,000	6,000,000
Net Cash Provided by (Used in) Investing Activities	3,000,000	(2,901,449)
Cash Flows from Financing Activities:
Issuance of common stock and units, net of issuance costs		7,653,828
Net Cash Provided by Financing Activities		7,653,828
Net Decrease in Cash and Cash Equivalents	(10,596)	(1,434,252)
Cash and Cash Equivalents - beginning of period	9,219,547	8,744,301
Cash and Cash Equivalents - end of period	9,208,951	7,310,049
Supplemental Cash Flow Information
Operating cash flows paid for amounts included in the measurement of lease liabilities	$ 76,843	120,700
Non-cash financing and investing activties:
Warrants issued		4,735,913
Operating lease right-of-use assets obtained in exchange for lease obligation		$ 380,935

Operations And Organization

Operations And Organization	6 Months Ended
	Jun. 30, 2020
Operations And Organization [Abstract]
Operations And Organization	1. Operations and Organization Operations Rexahn Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, is a biopharmaceutical company whose principal operations have been the development of innovative therapies to improve patient outcomes in cancers that are difficult to treat. The Company had an accumulated deficit of $166,420,604 at June 30, 2020 and anticipates incurring losses in the foreseeable future.  On June 17, 2020, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Original Merger Agreement,” and as amended on June 29, 2020, the “Merger Agreement”) with Razor Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Ocuphire Pharma Inc., a Delaware corporation (“Ocuphire”), pursuant to which, among other things, and subject to the satisfaction and waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Ocuphire, with Ocuphire continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the “Merger”). See Note 2, Merger Agreement and Pre-Merger Financing, for further information.  The Company believes that its cash and cash equivalents of approximately $9.2 million as of June 30, 2020 will be sufficient to cover its cash flow requirements for its current activities for at least the next 12 months from the date these financial statements were issued , assuming the Merger does not close .  Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete financial statements. In the opinion of the Company’s management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of June 30, 2020 and December 31, 2019 and of the results of operations, comprehensive loss, and stockholders’ equity for the three and six months ended June 30, 2020 and 2019 and the cash flows for the six months ended June 30, 2020 and 2019 have been included. Operating results for the three and six months ended June 30, 2020 are not necessarily indicative of results that may be expected for any other interim period or the full fiscal year ending December 31, 2020. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (the “2019 Form 10-K”). Information included in the condensed balance sheet as of December 31, 2019 has been derived from the Company’s audited financial statements for the year ended December 31, 2019 included in the 2019 Form 10-K. The unaudited condensed financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.  Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Actual results may ultimately differ from these estimates. These estimates are reviewed periodically, and as adjustments become necessary, they are reported in earnings in the period in which they become available.  COVID-19 Pandemic The outbreak of the COVID-19 disease, which the World Health Organization declared a pandemic in March 2020, has led to disruption in the global economy and the biopharmaceutical industry. The extent of the COVID-19 pandemic’s impact on the Company’s business, financial condition and results of operations, as well as the Company’s ability to consummate the Merger, is highly uncertain and will depend on various factors, including the duration and scope of the pandemic, restrictions on business and social distancing guidelines that may be requested or mandated by governmental authorities, other actions taken to contain the impact of the pandemic, and the Company’s access to additional capital.  

Merger Agreement and Pre-Merger

Merger Agreement and Pre-Merger Financing	6 Months Ended
	Jun. 30, 2020
Merger Agreement and Pre-Merger Financing [Abstract]
Merger Agreement and Pre-Merger Financing	2. Merger Agreement and Pre-Merger Financing  Merger Agreement On June 17, 2020, the Company, Merger Sub and Ocuphire entered into the Original Merger Agreement, which was subsequently amended on June 29, 2020, pursuant to which Merger Sub will merge with and into Ocuphire, with Ocuphire continuing as a wholly owned subsidiary of the Company in an all-stock transaction.  For accounting purposes, Ocuphire is considered to be acquiring the Company even though the Company will be the issuer of the common stock in the Merger due to various considerations, including the expected ownership positions of former Company and Ocuphire stockholders post-Merger, as well as the expected composition of the Company’s Board of Directors and management team post-Merger. The Merger is expected to be accounted for as an asset acquisition by Ocuphire.  Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the “Effective Time”): (a) each share of Ocuphire common stock outstanding immediately prior to the Effective Time (excluding shares held as treasury stock, shares held by Ocuphire and dissenting shares) will be converted into the right to receive shares of Company common stock equal to the Exchange Ratio described below; and (b) each outstanding Ocuphire stock option that has not previously been exercised prior to the Effective Time will be assumed by the Company.  Under the exchange ratio formula in the Merger Agreement (the “Exchange Ratio”), immediately following the consummation of the Merger (the “Closing”), the Company’s then-current stockholders would own approximately 14.3% of the combined company’s common stock, and the former Ocuphire securityholders would own approximately 85.7% of the combined company’s common stock, in each case calculated on a fully-diluted basis, assuming the Company’s net cash balance at the anticipated Closing date is between $3.2 million and $6.0 million. The Exchange Ratio formula in the Merger Agreement is subject to adjustment for every $100,000 that the Company’s actual net cash balance at the anticipated Closing date is less than $3.2 million or more than $6.0 million. Based on the Company’s current estimates, the Company anticipates delivering net cash between $0 and $500,000 assuming the Closing occurs by November 14, 2020, which is the end date set forth in the Merger Agreement; however, the final net cash amount will not be calculated until the anticipated Closing date, and may vary significantly depending on, among other things, the Company’s ability to control and correctly estimate its operating expenses, expenses relating to the Company’s ongoing litigation and the trading price of the Company’s common stock (and its impact on the estimated warrant liability, which reduces net cash). If the Company’s actual net cash balance at the anticipated Closing date is $0 , which is the minimum amount of net cash that the Company is required to deliver to Close, then immediately following the Closing, the Company’s then-current stockholders would own approximately 11.2% of the combined company’s common stock, and the former Ocuphire securityholders would own approximately 88.8% of the combined company’s common stock, in each case calculated on a fully-diluted basis. Under the terms of the Merger Agreement, the Company’s stockholders’ ownership percentage in the combined company is subject to a floor of 9.1% regardless of the Company’s actual net cash balance at the anticipated Closing date, assuming Ocuphire waives the minimum net cash requirement at the anticipated Closing date. These ownership percentages give effect to the shares of Ocuphire common stock that will be issued to Investors (as defined below) in the Pre-Merger Financing (as defined below) prior to the Closing, but do not account for any additional shares of Company common stock that may be issued following the Closing or the warrants issuable to Investors after Closing. As a result, holders of Company common stock could own significantly less of the combined company than currently contemplated. For example, if the average of the five lowest volume-weighted average trading prices of Company common stock on Nasdaq Capital Market (“Nasdaq”) during the first ten trading days immediately following the closing of the Pre-Merger Financing reaches a certain floor price specified in the Securities Purchase Agreement (as defined below), then the pre-Merger holders of Company common stock could own a low single-digit percentage of the fully-diluted combined company equity securities, depending on the Company’s actual net cash amount at the anticipated Closing date.  Consummation of the Merger is subject to certain Closing conditions, including, among other things: (i) approval by the stockholders of the Company and Ocuphire; (ii) the continued listing of the Company’s common stock on the Nasdaq and the listing of the additional shares of Company common stock issued in connection with the Merger on Nasdaq; (iii) the accuracy of the representations and warranties, subject to certain materiality qualifications; (iv) satisfaction by the Company of a minimum net cash requirement of $0 ; and (v) completion of the Pre-Merger Financing.  The Merger Agreement contains certain termination rights for both the Company and Ocuphire, and further provides that, upon termination of the Merger Agreement under specified circumstances, either party may be required to pay the other party a termination fee of $750,000 or, in some circumstances, Ocuphire may be required to reimburse the Company’s expenses up to a maximum of $750,000.  Immediately after the Effective Time, the Board of Directors of the Company is expected to be comprised of seven members, one of whom is expected to be Richard J. Rodgers, a current member of the Company’s Board of Directors, and the remaining six directors are expected to include existing Ocuphire board members and an additional director designated by Ocuphire. Following the Closing, Mina Sooch is expected to serve as the Company’s President and Chief Executive Officer. Also at the Effective Time, the Company expects to effect a name change to “Ocuphire Pharma, Inc.” and it is anticipated that the Company’s securities will be listed for trading on Nasdaq under the symbol “OCUP.”  In accordance with the Merger Agreement, on June 17, 2020, the Board of Directors approved the termination of Douglas J. Swirsky’s employment with the Company, effective as of immediately following the Effective Time, as a result of which Mr. Swirsky will be entitled to the severance amounts and other benefits afforded Mr. Swirsky in connection with a termination of Mr. Swirsky’s employment by the Company without cause within the two-year period immediately following a change of control pursuant to Section 8(c) of Mr. Swirsky’s employment agreement, subject to Mr. Swirsky’s execution of a general release in favor of the Company. The termination of Mr. Swirsky’s employment is subject to and conditioned upon the closing of the Merger at the Effective Time, and therefore Mr. Swirsky shall not be terminated if the Merger is not consummated or the Merger Agreement is terminated prior to the Effective Time.  The Merger is expected to close in the second half of 2020, subject to approval by the Company’s stockholders at a special meeting to be held at a future date and other closing conditions.  Contingent Value Rights Agreement Pursuant to the Merger Agreement and a Contingent Value Rights Agreement (the “CVR Agreement”) to be entered into immediately prior to Closing, Company stockholders as of immediately prior to the Effective Time will receive one contingent value right (“CVR”) for each share of Company common stock held of record as of immediately prior to the Effective Time. Each CVR will represent the right to receive cash payments upon the occurrence of certain triggering events. In particular, for each calendar quarter (each, a “CVR Payment Period”) during the 15 -year period after the Closing (the “CVR Term”), CVR holders will be entitled to (i) 90% of all payments received by the Company from BioSense Global LLC (“BioSense”) pursuant to that certain License and Assignment Agreement, dated as of February 25, 2019, by and between BioSense and the Company, as amended (the “License and Assignment Agreement”), less certain permitted deductions, (ii) 90% of all payments received by the Company from Zhejiang HaiChang Biotechnology Co., Ltd. (“HaiChang”) pursuant to that certain Exclusive License Agreement, dated as of February 8, 2020, by and between HaiChang and the Company (the “HaiChang License Agreement”), less certain permitted deductions, and (iii) 75% of (a) all cash consideration paid by a third party to the Company during the applicable CVR Payment Period in connection with the grant, sale or transfer of rights to certain of the Company’s pre-Closing intellectual property (“Parent IP”) under an agreement that is entered into during the 10 -year period after the Closing (“Parent IP Deal”); plus (b) with respect to any non-cash consideration received by the Company from a third party during the applicable CVR Payment Period in connection with any Parent IP Deal, all amounts received by the Company at the time such non-cash consideration is monetized, less (c) certain permitted deductions.  Securities Purchase Agreement On June 29, 2020, Ocuphire, the Company and certain institutional healthcare investors, accredited investors and certain directors and officers of Ocuphire (the “Investors”) entered into a Securities Purchase Agreement, which amended and restated in its entirety the prior securities purchase agreement among the same parties dated June 17, 2020 (the “Securities Purchase Agreement”). Pursuant to the Securities Purchase Agreement, the Investors agreed to invest a total of $21.15 million in cash (the “Purchase Price”) to fund the combined company following the Merger (the “Pre-Merger Financing”). In return, based on an agreed upon pre-money valuation of the combined company of $120 million, Ocuphire will issue shares of Ocuphire common stock to the Investors, which shares will be exchangeable in the Merger for approximately 15% of the combined company on a fully diluted basis (the “Initial Shares”). In addition, (i) Ocuphire will deposit three times the number of Initial Shares into escrow with an escrow agent for the benefit of the Investors, to be exchanged for Company common stock in the Merger, and to be delivered, in whole or in part, based on the formula set forth in the Securities Purchase Agreement, out of escrow to the Investors if 85% of the average of the five lowest volume-weighted average trading prices of a share of Company common stock on Nasdaq during the first ten trading days (or earlier, at the election of any Investor) immediately following the closing date of the Pre-Merger Financing (which closing date will be the same date as the Closing) is lower than the effective price per share paid by the Investors for the shares of Company common stock issued at Closing in exchange for the Initial Shares, and (ii) on the tenth trading day following the closing date of the Pre-Merger Financing (the “warrant closing date”), the Company will issue to the Investors (x) Series A warrants to purchase shares of Company common stock and (y) Series B warrants to purchase shares of Company common stock. 

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2020
Marketable Securities [Abstract]
Marketable Securities	3. Marketable Securities  Marketable securities are considered “available-for-sale” in accordance with Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 320, “Debt and Equity Securities,” and thus are reported at fair value in the Company’s accompanying balance sheet, with unrealized gains and losses excluded from earnings and reported as a separate component of stockholders’ equity. Amounts reclassified out of accumulated other comprehensive income (loss) into realized gains and losses are accounted for on the basis of specific identification and are included in other income or expense in the statement of operations. The Company classifies such investments as current on the balance sheet as the investments are readily marketable and available for use in current operations.  The Company had no marketable securities as of June 30, 2020. The following table shows the Company’s marketable securities’ adjusted cost, gross unrealized gains and losses, and fair value by significant investment category as of December 31, 2019:    December 31, 2019  Cost Gross Unrealized Gross Unrealized Fair  Basis Gains Losses Value  Commercial Paper $ 1,996,216 $ 1,184 $ - $ 1,997,400  Corporate Bonds 998,920 900 - 999,820  Total Marketable Securities $ 2,995,136 $ 2,084 $ - $ 2,997,220 

Equipment, Net

Equipment, Net	6 Months Ended
	Jun. 30, 2020
Equipment, Net [Abstract]
Equipment, Net	4. Equipment, Net    June 30, December 31,  2020 2019   Furniture and fixtures $ 67,650 $ 67,650  Office and computer equipment 163,440 163,440  Leasehold improvements 116,403 116,403   Total equipment 347,493 347,493  Less: Accumulated depreciation and amortization (290,181) (271,723)   Net carrying amount $ 57,312 $ 75,770 

Accounts Payable And Accrued Ex

Accounts Payable And Accrued Expenses	6 Months Ended
	Jun. 30, 2020
Accounts Payable And Accrued Expenses [Abstract]
Accounts Payable And Accrued Expenses	 5. Accounts Payable and Accrued Expenses     June 30, December 31,  2020 2019   Trade payables $ 1,651,659 $ 488,285  Accrued expenses 454,850 471,700  Accrued research and development contract costs - 221,170  Payroll liabilities 84,244 84,576   $ 2,190,753 $ 1,265,731 

License Agreements

License Agreements	6 Months Ended
	Jun. 30, 2020
License Agreements [Abstract]
License Agreements	 6. License Agreements  BioSense Global LLC On March 10, 2020, the Company entered into an amendment to its collaboration and license agreement, (as amended, the “License and Assignment Agreement”) with BioSense to advance the development and commercialization of RX-3117 for all human uses in the Republic of Singapore, China, Hong Kong, Macau, and Taiwan (the “Territory”). Under the terms of the License and Assignment Agreement, upon payment in full of an upfront payment, the Company will (i) grant BioSense an exclusive license to develop and commercialize pharmaceutical products containing RX-3117 as a single agent for all human uses in the Territory and (ii) assign and transfer all of the Company’s patents and patent applications related to RX-3117 in the Territory. The upfront payment consists of an aggregate of $1,650,000 , of which $1,550,000 has been received to date. Under the License and Assignment Agreement, the Company is eligible to receive milestone payments in an aggregate of up to $84,500,000 upon the achievement of development, regulatory and commercial goals and will also be eligible to receive tiered royalties in the mid-single digits to low tens on annual net sales in the Territory. The Company has evaluated the License and Assignment Agreement under ASC 606, “Revenue from Contracts with Customers,” to determine the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the License and Assignment Agreement. The Company identified the exclusive license to develop RX-3117 and the supply of RX-3117 drug product, drug substance and intermediate materials (collectively, the “Transferred Materials”) as the distinct performance obligations in the contract. The Company has determined that it will recognize revenue related to the exclusive license to develop RX-3117 and the supply of the Transferred Materials transfers to BioSense at a point in time when the exclusive license is conveyed and the Transferred Materials are made available for delivery to BioSense, respectively. The Company has determined the transaction price contains both fixed and variable consideration. The fixed consideration is equal to the upfront payment of $1,650,000 . The variable consideration relates to the milestone payments and future sales-based royalty payments. The Company estimates the variable consideration in the contract using the most likely amount method. The Company determined at the contract outset and as of June 30, 2020 that all milestone payments should be fully constrained, as it is not probable that a significant reversal of revenue will not occur in a future period, given the significance of the milestone payments and that the payments are earned based upon the achievement of events that are highly susceptible to factors outside of the Company’s control. Future sales-based royalties related to the exclusive license to develop RX-3117 will be recognized in the period the underlying sales transaction occurs. The $1,650,000 upfront payment has been allocated to the performance obligations on the basis of the relative standalone selling price estimated for each performance obligation. The Company has determined the standalone selling price of the exclusive license to develop RX-3117 using the adjusted market approach, which represents the price the market will bear based on the license rights granted and the state of the intellectual property, and has determined the standalone selling price of the supply of the Transferred Materials using a cost approach. Accordingly, the Company has allocated $750,000 of the upfront transaction price to the exclusive license to develop RX-3117 and $900,000 to the supply of the Transferred Materials. Additional transaction price recognized in future periods related to milestone payments and royalties will be allocated solely to the exclusive license to develop RX-3117, as these amounts relate to efforts associated with the development and commercialization of products related to the exclusive license to develop RX-3117. As of June 30, 2020, $1,550,000 of the upfront payment had been paid, and the remaining $100,000 remained unpaid. As of June 30, 2020, the exclusive license had not been transferred and no revenue was recognized related to that performance obligation, however, the Company had satisfied the performance obligation related to the Transferred Materials during the three months ended March 31, 2020. Therefore, the Company recognized no revenue and $900,000 in revenue for the three and six months ended June 30, 2020, respectively. Therefore, the Company has recorded the additional $650,000 of transaction consideration received as of June 30, 2020 as deferred revenue on the Company’s balance sheet. Zhejiang HaiChang Biotechnology Co., Ltd. On February 8, 2020, the Company entered into the HaiChang License Agreement with HaiChang pursuant to which the Company granted HaiChang an exclusive (even as to the Company), royalty-bearing, sublicensable worldwide license to research, develop and commercialize pharmaceutical products comprising RX-0201 (subject to and limited by the exclusive rights of NEXT BT Co. Ltd (“Next BT”) with respect to RX-0201 in Asia), the nano-liposomal formulation of RX-0201 known as RX-0301, and RX-0047, a proprietary compound currently in preclinical development. HaiChang has agreed to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize one product comprising RX-0301 and one product comprising RX-0047.  HaiChang paid a one-time upfront payment of $250,000 to the Company for certain materials to be transferred by the Company to HaiChang. HaiChang will pay the Company development milestone payments in an aggregate of up to $63,000,000 with respect to RX-0201 and RX-0301 and up to $33,000,000 with respect to RX-0047, and royalties based on percentages of net sales in the low tens with respect to RX-0201 and RX-0301 and the mid-single digits with respect to RX-0047. However, if HaiChang exclusively sublicenses its rights to a third party with respect to RX-0201 and RX-0301 or RX-0047 in a particular jurisdiction, instead of the foregoing milestones and royalties to the extent relating to such compound(s) and jurisdiction, HaiChang will pay the Company a percentage of any sublicensing revenue received by HaiChang, provided that in any event HaiChang will pay a milestone payment on initiation of a Phase 3 clinical trial that is subject to reduction by the amount of any sublicensing revenue paid with respect to the applicable compound(s) as of the time of initiation of the trial.  The Company accounts for the HaiChang License Agreement under ASC 606. The Company has determined the performance obligations under the contract relate to the transfer of materials and the license of intellectual property. Revenue associated with the materials and license is recognized at a point in time. The Company has determined the transaction price contains both fixed and variable consideration. The fixed consideration is equal to the upfront payment of $250,000 . At the outset of the contract, the Company determined the value of the license to be de minimis given the early stage of clinical development of the intellectual property, and allocated the entire fixed consideration to the materials. The Company transferred the materials during the three months ended March 31, 2020 and therefore recognized $0 and $250,000 in revenue during the three and six months ended June 30, 2020, respectively. The variable consideration relates to the milestone payments, sublicense fees and future sales-based royalty payments . The Company estimates variable consideration under the contract using the expected value method. Given the early stage and the uncertain success of the development work to be performed by HaiChang, the Company has determined that the variable consideration in the contract should be fully constrained at the contract outset and as of June 30, 2020.

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	7. Leases  The Company leases 5,466 square feet of office space in Rockville, Maryland, with a lease term ending June 30, 2024. Under the lease agreement, the Company pays its allocable portion of real estate taxes and common area operating charges, which are recorded as variable lease costs. The lease has escalating rent payments for which the Company records lease expense on a straight-line basis over the lease term, and an option to terminate the leased premises, without penalty, on June 30, 2021. The Company is reasonably certain that it will not remain in these leased premises after the optional termination date, and therefore, is using the optional termination date in assessing the lease term.  The components of lease expense were as follows:    For the Three Months Ended June 30, For the Six Months Ended June 30,  2020 2019 2020 2019  Operating lease cost $ 36,770 $ 47,129 $ 73,541 $ 127,407  Variable lease cost 6,110 6,659 11,803 22,672   Total Lease Cost $ 42,880 $ 53,788 $ 85,344 $ 150,079  The right-of-use asset and lease liability were calculated using an estimated incremental borrowing rate of 11% . At June 30, 2020, the weighted average lease term was 1.0 years.  The table below summarizes the Company’s scheduled future minimum lease payments recorded on the balance sheet, as of June 30, 2020:     Year Ending December 31:  2020 (excluding the six months ended June 30, 2020) $ 78,437  2021 65,364  Minimum lease payments 143,801  Less: Imputed interest (7,604)  Present value of minimum lease payments $ 136,197 

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2020
Net Loss Per Common Share [Abstract]
Net Loss Per Common Share	8. Net Loss per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding, plus the number of common share equivalents that would be dilutive. As of June 30, 2020 and December 31, 2019, there were stock options and warrants to acquire, in the aggregate, 2,067,713 and 2,126,063 shares of the Company’s common stock, respectively, that are potentially dilutive. However, diluted loss per share is the same as basic loss per share for all periods presented because the inclusion of common share equivalents would be anti-dilutive.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2020
Stock-Based Compensation [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation As of June 30, 2020, the Company had 146,224 options to purchase common stock outstanding. In June 2013, the Company’s shareholders voted to approve the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan (the “2013 Plan”). Under the 2013 Plan, the Company grants equity awards to key employees, directors and consultants of the Company. The Company has reserved 283,333 shares of common stock for issuance pursuant to the 2013 Plan. As of June 30, 2020, there were 142,066 options outstanding under the 2013 Plan, and 139,236 shares were available for issuance. In addition, as of June 30, 2020, there were 4,158 options outstanding under a previously established stock option plan under which no new stock options may be granted. Accounting for Awards Stock-based compensation expense is the estimated fair value of options granted amortized on a straight-line basis over the requisite vesting service period for the entire portion of the award. Total stock-based compensation recognized by the Company for the three and six months ended June 30, 2020 and 2019 is as follows:    For the Three Months Ended June 30, For the Six Months Ended June 30,  2020 2019 2020 2019  Statement of operations line item:  General and administrative $ 66,351 $ 119,719 $ 138,771 $ 236,398  Research and development 2,718 7,934 6,600 52,255   Total $ 69,069 $ 127,653 $ 145,371 $ 288,653  No income tax benefit has been recognized in the statement of operations for stock-based compensation arrangements as the Company has provided for a 100 % valuation allowance on its deferred tax assets. Summary of Stock Option Transactions  A summary of stock option activity for the six months ended June 30, 2020 is as follows:     Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value  Outstanding, January 1, 2020 204,574 $ 35.60 7.3 years $ -  Granted - $ -  Exercised - $ -  Expired (2,996) $ 156.41  Cancelled (55,354) $ 59.54   Outstanding, June 30, 2020 146,224 $ 24.06 7.6 years $ -  Exercisable, June 30, 2020 98,834 $ 28.65 7.3 years $ -  A summary of the Company’s unvested options as of June 30, 2020 and changes during the six months ended June 30, 2020 is presented below:     2020  Number of Options Weighted Average Fair Value at Grant Date  Unvested at January 1, 2020 81,311 $ 7.90  Granted - $ -  Vested (33,127) $ 5.53  Cancelled (794) $ 9.12   Unvested at June 30, 2020 47,390 $ 9.55 As of June 30, 2020, there was $425,525 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted average vesting period of 2.0 years.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2020
Warrants [Abstract]
Warrants	10. Warrants The following table summarizes the Company’s outstanding warrants to purchase common stock as of June 30, 2020 and December 31, 2019:     Number of Warrants:  Warrant Issuance June 30, 2020 December 31, 2019 Exercise Price Expiration Date  Liability-classified Warrants  November 2015 Investors 104,168 104,168 $ 63.60 May 2021  November 2015 Placement Agent 279 279 $ 63.60 Nov. 2020  March 2016 Investors 50,651 50,651 $ 50.40 Sept. 2021  September 2016 Investors 67,084 67,084 $ 36.00 Mar. 2022  June 2017 Investors 126,264 126,264 $ 48.00 Dec. 2022  June 2017 Placement Agent 15,153 15,153 $ 49.50 June 2022  October 2017 Investors 136,058 136,058 $ 34.20 Apr. 2023  October 2017 Placement Agent 16,327 16,327 $ 36.72 Oct. 2022  Total liability classified warrants 515,984 515,984   Equity-classified Warrants  October 2018 Investors 480,771 480,771 $ 20.04 Apr. 2024  October 2018 Placement Agent 28,848 28,848 $ 19.50 Oct. 2023  January 2019 Investors 895,886 895,886 $ 9.60 Jan. 2024  Total equity-classified warrants 1,405,505 1,405,505   Total outstanding warrants 1,921,489 1,921,489  The following table summarizes the Company’s warrant activity for the six months ended June 30, 2020:      Number of Warrants  Liability-classified Equity- classified Total Weighted average exercise price  Balance, January 1, 2020 515,984 1,405,505 1,921,489 $ 22.10  Issued during the period - - - $ -  Exercised during the period - - - $ -  Expired during the period - - - $ -   Balance, June 30, 2020 515,984 1,405,505 1,921,489 $ 22.10 At June 30, 2020, the weighted average remaining contractual life of the outstanding warrants was 3.2 years. The following table summarizes the fair value of the liability-classified warrants as of the respective balance sheet dates:    Fair Value as of:  Warrant Issuance: June 30, 2020 December 31, 2019  November 2015 Investors $ 3,286 $ 55  November 2015 Placement Agent - -  March 2016 Investor 6,362 439  September 2016 Investors 28,765 3,196  June 2017 Investors 83,463 11,736  June 2017 Placement Agent 6,348 845  October 2017 Investors 129,299 23,772  October 2017 Placement Agent 11,288 1,674  Total: $ 268,811 $ 41,717  The assumptions used in calculating the fair values of the liability-classified warrants are as follows:     June 30, 2020 December 31, 2019  Trading market prices $ 2.84 $ 1.91  Fundamental transaction volatility 134 % 102 %  Dividend - -  Fundamental transaction risk-free rate 0.17 -0.21 % 1.57 -1.72 %  Equivalent volatility 92 -103% % 85-94 %  Equivalent risk-free rate 0.16 % 1.57 -1.59 %  Fundamental transaction likelihood 90 % 50 %  Fundamental transaction timing September 2020 April 2020  As discussed in Note 2, on June 17, 2020, the Company entered into the Original Merger Agreement, which meets the definition of a fundamental transaction as defined by the warrant agreements. Therefore, the Company adjusted the likelihood and timing of its fundamental transaction assumptions when calculating the fair values of the liability-classified warrants as of June 30, 2020. Changes in the fair value of the warrant liabilities, carried at fair value, reported as “unrealized (loss) gain on fair value of warrants” in the statement of operations:     For the Three Months Ended June 30, For the Six Months Ended June 30,  2020 2019 2020 2019  November 2015 Investors $ (2,315) $ 27,069 $ (3,231) $ 224,153  November 2015 Placement Agent - 55 - 435  March 2016 Investors (5,122) 32,874 (5,923) 147,673  September 2016 Investors (14,126) 72,213 (25,569) 290,082  June 2017 Investors (53,099) 129,559 (71,727) 517,950  June 2017 Placement Agent (3,774) 14,553 (5,503) 56,464  October 2017 Investors (83,121) 135,125 (105,527) 631,626  October 2017 Placement Agent (7,145) 16,035 (9,614) 72,471  Total: $ (168,702) $ 427,483 $ (227,094) $ 1,940,854 

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Taxes [Abstract]
Income Taxes	11. Income Taxes No provision for federal and state income taxes was required for the three and six months ended June 30, 2020 and 2019 due to the Company’s operating losses and increased deferred tax asset valuation allowance. At June 30, 2020 and December 31, 2019, the Company had unused net operating loss carry-forwards of approximately $160,154,000 and $ 156,586 ,000 respectively, portions of which expire at various dates beginning in 2021. Some of the Company’s unused net operating loss carryforwards may be subject to annual limitations under certain provisions of the Internal Revenue Code related to “changes in ownership.” As of June 30, 2020 and December 31, 2019, the deferred tax assets related to the aforementioned carry-forwards have been fully offset by valuation allowances, because significant utilization of such amounts is not presently expected in the foreseeable future. Deferred tax assets and valuation allowances consist of:     June 30, December 31,  2020 2019   Net Operating Loss Carryforwards $ 44,843,000 $ 43,844,000  Stock Compensation Expense 540,000 1,191,000  Book Tax Differences on Assets and Liabilities 227,000 464,000  Valuation Allowance (45,610,000) (45,499,000)   Net Deferred Tax Assets $ - $ - The Company files income tax returns in the U.S. federal and Maryland state jurisdictions. Tax years for fiscal 2016 through 2019 are open and potentially subject to examination by the federal and Maryland state taxing authorities.

Commitments And Contingencies

Commitments And Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies [Abstract]
Commitments And Contingencies	12. Commitments and Contingencies a) The Company has contracted with various vendors for services, with terms that require payments over the terms of the agreements, usually ranging from two to 36 months. The costs to be incurred are estimated and are subject to revision. As of June 30, 2020, the total estimated cost to complete these agreements was approximately $210,000 . All of these agreements may be terminated by either party upon appropriate notice as stipulated in the respective agreements. b) On June 22, 2009, the Company entered into a License Agreement with Korea Research Institute of Chemical Technology (“KRICT”) to acquire the rights to all intellectual property related to quinoxaline-piperazine derivatives that were synthesized under a Joint Research Agreement. The agreement with KRICT calls for a one-time milestone payment of $ 1,000,000 within 30 days after the first achievement of marketing approval of the first commercial product arising out of or in connection with the use of KRICT’s intellectual property. As of June 30, 2020, the milestone has not occurred. c) The Company has established a 401(k) plan for its employees. The Company has elected to match 100% of the first 3% of an employee’s compensation plus 50% of an additional 2% of the employee’s deferral. Expense related to this matching contribution aggregated to $9,785 and $18,506 for the three months ended June 30, 2020 and 2019, respectively, and $21,014 and $46,385 for the six months ended June 30, 2020 and 2019, respectively. d) On February 5, 2018, the Company and Next BT terminated a research collaboration agreement between the Company and Rexgene Biotech Co., Ltd, a predecessor in interest to Next BT. The Company agreed to pay Next BT a royalty in the low single digits of any net sales of RX-0201 the Company makes in Asia and 50% of the Company’s licensing revenue related to licensing of RX-0201 in Asia, up to an aggregate of $5,000,000 . On June 18, 2018, the Company reinstated the exclusive license to RX-0201 in Asia, which had no effect on the potential royalty payments granted to Next BT in February 2018 . As of June 30, 2020, the Company has not made any royalty payments to Next BT. 

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Measurements [Abstract]
Fair Value Measurements	13. Fair Value Measurements ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).  The three levels are described below:  Level 1 Inputs — Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible by the Company; Level 2 Inputs — Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; Level 3 Inputs — Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.  The following tables present assets and liabilities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. de    Fair Value Measurements at June 30, 2020  Total Level 1 Level 2 Level 3  Liabilities:  Warrant Liabilities $ 268,811 $ - $ - $ 268,811     Fair Value Measurements at December 31, 2019  Total Level 1 Level 2 Level 3  Assets:  Commercial Paper $ 1,997,400 $ - $ 1,997,400 $ -  Corporate Bonds 999,820 - 999,820 -  Total Assets: $ 2,997,220 $ - $ 2,997,220 $ -   Liabilities:  Warrant Liabilities $ 41,717 $ - $ - $ 41,717  There have been no changes in the methodologies used at June 30, 2020 and December 31, 2019, and no transfers between Level 1, 2 and 3 during the six months ended June 30, 2020.  The reconciliation of changes to the fair value of the Company’s warrant liabilities for the six months ended June 30, 2020 is as follows:     Warrant Liabilities  Balance at January 1, 2020 $ 41,717  Unrealized losses, net 227,094  Balance at June 30, 2020 $ 268,811

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2020
Subsequent Event [Abstract]
Subsequent Event	14. Subsequent Event s  Warrant Exchange Agreement  On July 31, 2020, the Compan y entered into a Warrant Exchange Agreement with Armistice Capital Master Fund Ltd. (“Armistice”) p ursuant to which , on August 3, 2020, the Company issu ed to Armistice an aggregate of 215,000 shares of c ommon s tock of the Company in exchange for the surrender and cancellation of 160,257 and 208,334 of the October 2018 and January 2019 Investor Warrants held by Armistice, respectively.  Legal Proceedings  On July 31, 2020, a putative stockholder class action was filed in the Court of Chancery of the State of Delaware styled Stahlman v. Rexahn Pharmaceuticals, Inc., et al., Case No. 2020-0639. Additionally, on August 3, 2020, a putative stockholder class action was filed in the United States District Court for the District of Delaware styled Thompson v. Rexahn Pharmaceuticals, Inc., et al. , Case No. 1:20-cv-01036-UNA (D. Del). On August 7, 2020, a putative stockholder class action was filed in the United States District Court for the Southern District of New York styled Manes v. Rexahn Pharmaceuticals, Inc., et al., Case No. 1:20-cv-06227 (S.D.N.Y.) (together with the Stahlman and Thompson actions, the “Stockholder Actions”). The Stockholder Actions assert claims against the Company and members of the Company’s board of directors (the “Individual Defendants”).  The Stahlman and Manes complaints allege that the Individual Defendants breached their fiduciary duties owed to the Company’s stockholders. The Thompson and Manes complaints allege that the Company and the Individual Defendants violated Section 14(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 14a-9 promulgated thereunder, by failing to disclose in the Registration Statement on Form S-4 that the Company filed with the SEC on July 6, 2020 (File No. 333-239702) (the “Registration Statement”) certain information regarding, among other things, financial projections for the Company and Ocuphire, the valuation analyses performed by the Company’s financial advisor, Oppenheimer & Co., Inc., in support of its fairness opinion and the process leading to the execution of the Merger Agreement. The Thompson and Manes complaints also allege that the Individual Defendants violated Section 20(a) of the Exchange Act, as control persons who had the ability to prevent the Proxy Statement from being false and misleading. The Stockholder Actions seek, among other things, an injunction preventing consummation of the Merger, an award of damages, and an award of costs and expenses, including attorneys’ fees.  Additionally, on August 6, 2020, another party sent a letter to the Company’s counsel demanding that the Company and the Individual Defendants amend the Registration Statement to provide additional disclosures that the party alleges were improperly omitted from the Registration Statement in violation of Sections 14(a) and 20(a) of the Exchange Act, including certain information regarding financial data and the background and process leading to the execution of the Merger Agreement (the “Demand Letter”).  The Company intends to defend against the Stockholder Actions and the Demand Letter, however it is reasonably possible that a loss may be incurred. At this time, the Company is unable to estimate the potential loss or range of losses.  

Operations And Organization (Po

Operations And Organization (Policies)	6 Months Ended
	Jun. 30, 2020
Operations And Organization [Abstract]
Operations	Operations Rexahn Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, is a biopharmaceutical company whose principal operations have been the development of innovative therapies to improve patient outcomes in cancers that are difficult to treat. The Company had an accumulated deficit of $166,420,604 at June 30, 2020 and anticipates incurring losses in the foreseeable future.  On June 17, 2020, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Original Merger Agreement,” and as amended on June 29, 2020, the “Merger Agreement”) with Razor Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Ocuphire Pharma Inc., a Delaware corporation (“Ocuphire”), pursuant to which, among other things, and subject to the satisfaction and waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Ocuphire, with Ocuphire continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the “Merger”). See Note 2, Merger Agreement and Pre-Merger Financing, for further information.  The Company believes that its cash and cash equivalents of approximately $9.2 million as of June 30, 2020 will be sufficient to cover its cash flow requirements for its current activities for at least the next 12 months from the date these financial statements were issued , assuming the Merger does not close .
Basis Of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete financial statements. In the opinion of the Company’s management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of June 30, 2020 and December 31, 2019 and of the results of operations, comprehensive loss, and stockholders’ equity for the three and six months ended June 30, 2020 and 2019 and the cash flows for the six months ended June 30, 2020 and 2019 have been included. Operating results for the three and six months ended June 30, 2020 are not necessarily indicative of results that may be expected for any other interim period or the full fiscal year ending December 31, 2020. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (the “2019 Form 10-K”). Information included in the condensed balance sheet as of December 31, 2019 has been derived from the Company’s audited financial statements for the year ended December 31, 2019 included in the 2019 Form 10-K. The unaudited condensed financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. 
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Actual results may ultimately differ from these estimates. These estimates are reviewed periodically, and as adjustments become necessary, they are reported in earnings in the period in which they become available.
COVID-19 Pandemic	COVID-19 Pandemic The outbreak of the COVID-19 disease, which the World Health Organization declared a pandemic in March 2020, has led to disruption in the global economy and the biopharmaceutical industry. The extent of the COVID-19 pandemic’s impact on the Company’s business, financial condition and results of operations, as well as the Company’s ability to consummate the Merger, is highly uncertain and will depend on various factors, including the duration and scope of the pandemic, restrictions on business and social distancing guidelines that may be requested or mandated by governmental authorities, other actions taken to contain the impact of the pandemic, and the Company’s access to additional capital.

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2020
Marketable Securities [Abstract]
Schedule Of Cost And Fair Value Of Marketable Securities	  December 31, 2019  Cost Gross Unrealized Gross Unrealized Fair  Basis Gains Losses Value  Commercial Paper $ 1,996,216 $ 1,184 $ - $ 1,997,400  Corporate Bonds 998,920 900 - 999,820  Total Marketable Securities $ 2,995,136 $ 2,084 $ - $ 2,997,220 

Equipment, Net (Tables)

Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2020
Equipment, Net [Abstract]
Schedule Of Equipment, Net	  June 30, December 31,  2020 2019   Furniture and fixtures $ 67,650 $ 67,650  Office and computer equipment 163,440 163,440  Leasehold improvements 116,403 116,403   Total equipment 347,493 347,493  Less: Accumulated depreciation and amortization (290,181) (271,723)   Net carrying amount $ 57,312 $ 75,770 

Accounts Payable And Accrued _2

Accounts Payable And Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2020
Accounts Payable And Accrued Expenses [Abstract]
Schedule Of Accounts Payable And Accrued Expenses	  June 30, December 31,  2020 2019   Trade payables $ 1,651,659 $ 488,285  Accrued expenses 454,850 471,700  Accrued research and development contract costs - 221,170  Payroll liabilities 84,244 84,576   $ 2,190,753 $ 1,265,731 

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Components Of Lease Expense	  For the Three Months Ended June 30, For the Six Months Ended June 30,  2020 2019 2020 2019  Operating lease cost $ 36,770 $ 47,129 $ 73,541 $ 127,407  Variable lease cost 6,110 6,659 11,803 22,672   Total Lease Cost $ 42,880 $ 53,788 $ 85,344 $ 150,079 
Scheduled Future Minimum Lease Payments	  Year Ending December 31:  2020 (excluding the six months ended June 30, 2020) $ 78,437  2021 65,364  Minimum lease payments 143,801  Less: Imputed interest (7,604)  Present value of minimum lease payments $ 136,197 

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Stock-Based Compensation [Abstract]
Summary Of Stock Compensation Expense	  For the Three Months Ended June 30, For the Six Months Ended June 30,  2020 2019 2020 2019  Statement of operations line item:  General and administrative $ 66,351 $ 119,719 $ 138,771 $ 236,398  Research and development 2,718 7,934 6,600 52,255   Total $ 69,069 $ 127,653 $ 145,371 $ 288,653 
Summary Of Share-Based Transactions	   Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value  Outstanding, January 1, 2020 204,574 $ 35.60 7.3 years $ -  Granted - $ -  Exercised - $ -  Expired (2,996) $ 156.41  Cancelled (55,354) $ 59.54   Outstanding, June 30, 2020 146,224 $ 24.06 7.6 years $ -  Exercisable, June 30, 2020 98,834 $ 28.65 7.3 years $ - 
Summary Of Unvested Shares	   2020  Number of Options Weighted Average Fair Value at Grant Date  Unvested at January 1, 2020 81,311 $ 7.90  Granted - $ -  Vested (33,127) $ 5.53  Cancelled (794) $ 9.12   Unvested at June 30, 2020 47,390 $ 9.55 

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2020
Warrants [Abstract]
Summary Of Warrants Outstanding	  Number of Warrants:  Warrant Issuance June 30, 2020 December 31, 2019 Exercise Price Expiration Date  Liability-classified Warrants  November 2015 Investors 104,168 104,168 $ 63.60 May 2021  November 2015 Placement Agent 279 279 $ 63.60 Nov. 2020  March 2016 Investors 50,651 50,651 $ 50.40 Sept. 2021  September 2016 Investors 67,084 67,084 $ 36.00 Mar. 2022  June 2017 Investors 126,264 126,264 $ 48.00 Dec. 2022  June 2017 Placement Agent 15,153 15,153 $ 49.50 June 2022  October 2017 Investors 136,058 136,058 $ 34.20 Apr. 2023  October 2017 Placement Agent 16,327 16,327 $ 36.72 Oct. 2022  Total liability classified warrants 515,984 515,984   Equity-classified Warrants  October 2018 Investors 480,771 480,771 $ 20.04 Apr. 2024  October 2018 Placement Agent 28,848 28,848 $ 19.50 Oct. 2023  January 2019 Investors 895,886 895,886 $ 9.60 Jan. 2024  Total equity-classified warrants 1,405,505 1,405,505   Total outstanding warrants 1,921,489 1,921,489 
Summary Of Changes In Warrants Outstanding During The Period	  Number of Warrants  Liability-classified Equity- classified Total Weighted average exercise price  Balance, January 1, 2020 515,984 1,405,505 1,921,489 $ 22.10  Issued during the period - - - $ -  Exercised during the period - - - $ -  Expired during the period - - - $ -   Balance, June 30, 2020 515,984 1,405,505 1,921,489 $ 22.10 
Schedule Of Fair Value Of Warrants Issued	  Fair Value as of:  Warrant Issuance: June 30, 2020 December 31, 2019  November 2015 Investors $ 3,286 $ 55  November 2015 Placement Agent - -  March 2016 Investor 6,362 439  September 2016 Investors 28,765 3,196  June 2017 Investors 83,463 11,736  June 2017 Placement Agent 6,348 845  October 2017 Investors 129,299 23,772  October 2017 Placement Agent 11,288 1,674  Total: $ 268,811 $ 41,717 
Schedule Of Assumptions Used In Calculating Fair Value Of Warrants	   June 30, 2020 December 31, 2019  Trading market prices $ 2.84 $ 1.91  Fundamental transaction volatility 134 % 102 %  Dividend - -  Fundamental transaction risk-free rate 0.17 -0.21 % 1.57 -1.72 %  Equivalent volatility 92 -103% % 85-94 %  Equivalent risk-free rate 0.16 % 1.57 -1.59 %  Fundamental transaction likelihood 90 % 50 %  Fundamental transaction timing September 2020 April 2020 
Schedule Of Unrealized Gain/(Loss) On Fair Value Of Warrants	  For the Three Months Ended June 30, For the Six Months Ended June 30,  2020 2019 2020 2019  November 2015 Investors $ (2,315) $ 27,069 $ (3,231) $ 224,153  November 2015 Placement Agent - 55 - 435  March 2016 Investors (5,122) 32,874 (5,923) 147,673  September 2016 Investors (14,126) 72,213 (25,569) 290,082  June 2017 Investors (53,099) 129,559 (71,727) 517,950  June 2017 Placement Agent (3,774) 14,553 (5,503) 56,464  October 2017 Investors (83,121) 135,125 (105,527) 631,626  October 2017 Placement Agent (7,145) 16,035 (9,614) 72,471  Total: $ (168,702) $ 427,483 $ (227,094) $ 1,940,854 

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2020
Income Taxes [Abstract]
Schedule Of Deferred Tax Assets And Valuation Allowance	   June 30, December 31,  2020 2019   Net Operating Loss Carryforwards $ 44,843,000 $ 43,844,000  Stock Compensation Expense 540,000 1,191,000  Book Tax Differences on Assets and Liabilities 227,000 464,000  Valuation Allowance (45,610,000) (45,499,000)   Net Deferred Tax Assets $ - $ - 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Measurements [Abstract]
Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis	   Fair Value Measurements at June 30, 2020  Total Level 1 Level 2 Level 3  Liabilities:  Warrant Liabilities $ 268,811 $ - $ - $ 268,811     Fair Value Measurements at December 31, 2019  Total Level 1 Level 2 Level 3  Assets:  Commercial Paper $ 1,997,400 $ - $ 1,997,400 $ -  Corporate Bonds 999,820 - 999,820 -  Total Assets: $ 2,997,220 $ - $ 2,997,220 $ -   Liabilities:  Warrant Liabilities $ 41,717 $ - $ - $ 41,717 
Reconciliation Of Changes In The Fair Value Of Liabilities	  Warrant Liabilities  Balance at January 1, 2020 $ 41,717  Unrealized losses, net 227,094  Balance at June 30, 2020 $ 268,811 

Operations And Organization (De

Operations And Organization (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Operations And Organization [Abstract]
Cash, cash equivalents and marketable securities	$ 9,200,000
Accumulated deficit	$ 166,420,604	$ 163,322,676

Merger Agreement and Pre-Merg_2

Merger Agreement and Pre-Merger Financing (Details)	Jun. 29, 2020USD ($)item	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Business Acquisition [Line Items]
Cash and cash equivalents		$ 9,208,951	$ 9,219,547	$ 7,310,049	$ 8,744,301
Adjustment to Exchange Ration Formula	$ 100,000
Cash Requirement	0
Termination Fee	$ 750,000
Contingent Value Rights, License, Term		15 years
Contingent Value Rights, Percentage	90.00%
Contingent Value Rights, IP, Percentage	75.00%
Contingent Value Rights, IP, Term		10 years
Pre-Merger Financing	$ 21,150,000
Pre-Merger Valuation	$ 120,000,000
Pre-Merger Financing Ownership Of Combined Company	15.00%
Average Of Five Lowest Volume-Weighted Average Trading Prices	85.00%
Cash At Closing	$ 0
Post-Merger [Member]
Business Acquisition [Line Items]
Number Of Board Members | item	7
Rexahn [Member]
Business Acquisition [Line Items]
Share Ownership Percentage	14.30%
Number Of Board Members | item	1
Ocuphire [Member]
Business Acquisition [Line Items]
Share Ownership Percentage	85.70%
Number Of Board Members | item	6
0 Cash Balance [Member] | Rexahn [Member]
Business Acquisition [Line Items]
Share Ownership Percentage	11.20%
0 Cash Balance [Member] | Ocuphire [Member]
Business Acquisition [Line Items]
Share Ownership Percentage	88.80%
Minimum [Member] | Current Shareholders [Member]
Business Acquisition [Line Items]
Share Ownership Percentage	9.10%
Minimum [Member] | Post-Merger [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	$ 3,200,000
Estimated Cash Delivery Upon Closing	0
Maximum [Member] | Post-Merger [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	6,000,000
Estimated Cash Delivery Upon Closing	$ 500,000

Marketable Securities (Details)

Marketable Securities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Schedule of Available-for-sale Securities [Line Items]
Cost Basis		$ 2,995,136
Gross Unrealized Gains		2,084
Fair Value	$ 0	2,997,220
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost Basis		1,996,216
Gross Unrealized Gains		1,184
Fair Value		1,997,400
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost Basis		998,920
Gross Unrealized Gains		900
Fair Value		$ 999,820

Equipment, Net (Details)

Equipment, Net (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Total equipment	$ 347,493	$ 347,493
Less: Accumulated depreciation and amortization	(290,181)	(271,723)
Net carrying amount	57,312	75,770
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total equipment	67,650	67,650
Office And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total equipment	163,440	163,440
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total equipment	$ 116,403	$ 116,403

Accounts Payable And Accrued _3

Accounts Payable And Accrued Expenses (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accounts Payable And Accrued Expenses [Abstract]
Trade payables	$ 1,651,659	$ 488,285
Accrued expenses	454,850	471,700
Accrued research and development contract costs		221,170
Payroll liabilities	84,244	84,576
Total accounts payable and accrued expenses	$ 2,190,753	$ 1,265,731

License Agreements (Details)

License Agreements (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Deferred revenue	$ 650,000	$ 650,000	$ 1,500,000
BioSense Global LLC [Member]
Upfront payment		1,650,000
Amount received from upfront payment		1,550,000
Deferred revenue	650,000	650,000
Amount due	100,000	100,000
Milestone payment	84,500,000	84,500,000
BioSense Global LLC [Member] | RX-3117 License [Member]
Upfront payment		750,000
Revenue recognized		0
BioSense Global LLC [Member] | RX-3117 Material [Member]
Revenue recognized	0	900,000
Zhejiang HaiChang Biotechnology Co., Ltd. [Member]
Upfront payment		250,000
Revenue recognized	0	250,000
Fixed consideration		250,000
Zhejiang HaiChang Biotechnology Co., Ltd. [Member] | RX-0047 [Member]
Milestone payment	33,000,000	33,000,000
Zhejiang HaiChang Biotechnology Co., Ltd. [Member] | RX-0301 And RX-0201 [Member]
Milestone payment	$ 63,000,000	$ 63,000,000

Leases (Narrative) (Details)

Leases (Narrative) (Details)	Jun. 30, 2020ft²
Lessee, Lease, Description [Line Items]
Discount rate	11.00%
Weighted average lease term	1 year
Office Space Rental [Member]
Lessee, Lease, Description [Line Items]
Area	5,466

Leases (Components Of Lease Exp

Leases (Components Of Lease Expense) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Operating lease cost	$ 36,770	$ 47,129	$ 73,541	$ 127,407
Variable lease cost	6,110	6,659	11,803	22,672
Total Lease Cost	$ 42,880	$ 53,788	$ 85,344	$ 150,079

Leases (Scheduled Future Minimu

Leases (Scheduled Future Minimum Lease Payments) (Details)	Jun. 30, 2020USD ($)
Leases [Abstract]
2020 (excluding the six months ended June 30, 2020)	$ 78,437
2021	65,364
Minimum lease payments	143,801
Less: Imputed interest	(7,604)
Present value of minimum lease payments	$ 136,197

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Stock Options, Restricted Stock Units And Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	2,067,713	2,126,063

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Income tax benefit from share-based compensation	$ 0
Valuation allowance on deferred tax assets	100.00%
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	146,224	204,574
Unrecognized compensation cost	$ 425,525
Weighted average vesting period, years	2 years
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options authorized for issuance	283,333
Shares available for issuance	139,236
The 2013 Plan [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	142,066
The 2003 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance	0
The 2003 Plan [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	4,158

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary Of Stock Compensation Expense) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share Based Compensation	$ 69,069	$ 127,653	$ 145,371	$ 288,653
General and administrative [Member]
Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share Based Compensation	66,351	119,719	138,771	236,398
Research and development [Member]
Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share Based Compensation	$ 2,718	$ 7,934	$ 6,600	$ 52,255

Stock-Based Compensation (Sum_2

Stock-Based Compensation (Summary Of Share-Based Transactions ) (Details) - Stock Option [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Number of Options, Oustanding	204,574
Number of Options, Granted
Number of Options, Exercised
Number of Options, Expired	(2,996)
Number of Options, Cancelled	(55,354)
Number of Options, Oustanding	146,224	204,574
Weighted Average Exercise Price, Outstanding	$ 35.60
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	(156.41)
Weighted Average Exercise Price, Cancelled	59.54
Weighted Average Exercise Price, Outstanding	$ 24.06	$ 35.60
Weighted Average Remaining Contractual Term, Outstanding	7 years 7 months 6 days	7 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding
Number of Options, Exercisable	98,834
Weighted Average Exercise Price, Exercisable	$ 28.65
Weighted Average Remaining Contractual Term, Exercisable	7 years 3 months 18 days
Aggregate Intrinsic Value, Exercisable

Stock-Based Compensation (Sum_3

Stock-Based Compensation (Summary Of Unvested Shares) (Details) - Stock Option [Member]	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of Options, Unvested | shares	81,311
Number of Options, Granted | shares
Number of Options, Vested | shares	(33,127)
Number of Options, Cancelled | shares	(794)
Number of Options, Unvested | shares	47,390
Weighted Average Fair Value at Grant Date, Unvested | $ / shares	$ 7.90
Weighted Average Fair Value at Grant Date, Granted | $ / shares
Weighted Average Fair Value at Grant Date, Vested | $ / shares	5.53
Weighted Average Fair Value at Grant Date, Cancelled | $ / shares	9.12
Weighted Average Fair Value at Grant Date, Unvested | $ / shares	$ 9.55

Warrants (Narrative) (Details)

Warrants (Narrative) (Details)	6 Months Ended
	Jun. 30, 2020
Warrants [Abstract]
Average remaining contractual life of warrants outstanding	3 years 2 months 12 days

Warrants (Summary Of Warrants O

Warrants (Summary Of Warrants Outstanding) (Details) - $ / shares	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Number of Warrants	1,921,489	1,921,489
Liability-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	515,984	515,984
Equity-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	1,405,505	1,405,505
November 2015 Investor Warrants [Member] | Liability-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	104,168	104,168
Exercise Price	$ 63.60
Expiration Date	2021-05
November 2015 Placement Agent Warrants [Member] | Liability-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	279	279
Exercise Price	$ 63.60
Expiration Date	2020-11
March 2016 Investor Warrants [Member] | Liability-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	50,651	50,651
Exercise Price	$ 50.40
Expiration Date	2021-09
September 2016 Investor Warrants [Member] | Liability-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	67,084	67,084
Exercise Price	$ 36
Expiration Date	2022-03
June 2017 Investor Warrants [Member] | Liability-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	126,264	126,264
Exercise Price	$ 48
Expiration Date	2022-12
June 2017 Placement Agent Warrants [Member] | Liability-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	15,153	15,153
Exercise Price	$ 49.50
Expiration Date	2022-06
October 2017 Investor Warrants [Member] | Liability-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	136,058	136,058
Exercise Price	$ 34.20
Expiration Date	2023-04
October 2017 Placement Agent Warrants [Member] | Liability-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	16,327	16,327
Exercise Price	$ 36.72
Expiration Date	2022-10
October 2018 Investor Warrants [Member] | Equity-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	480,771	480,771
Exercise Price	$ 20.04
Expiration Date	2024-04
October 2018 Placement Agent Warrants [Member] | Equity-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	28,848	28,848
Exercise Price	$ 19.50
Expiration Date	2023-10
January 2019 Investor Warrants [Member] | Equity-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	895,886	895,886
Exercise Price	$ 9.60
Expiration Date	2024-01

Warrants (Summary Of Changes In

Warrants (Summary Of Changes In Warrants Outstanding During The Period) (Details)	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Class of Warrant or Right [Line Items]
Number of warrants, Outstanding	1,921,489
Number of warrants, issued
Number of warrants, Exercised
Number of warrants, Expired
Number of warrants, Outstanding	1,921,489
Weigted average exercise price, Outstanding | $ / shares	$ 22.10
Weighted average exercise price, Issued | $ / shares
Weighted average exercise price, Exercised | $ / shares
Weighted average exercise price, Expired | $ / shares
Weigted average exercise price, Outstanding | $ / shares	$ 22.10
Liability-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, Outstanding	515,984
Number of warrants, issued
Number of warrants, Exercised
Number of warrants, Expired
Number of warrants, Outstanding	515,984
Equity-Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, Outstanding	1,405,505
Number of warrants, issued
Number of warrants, Exercised
Number of warrants, Expired
Number of warrants, Outstanding	1,405,505

Warrants (Schedule Of Fair Valu

Warrants (Schedule Of Fair Value Of Warrants Issued) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Fair value	$ 268,811	$ 41,717
November 2015 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	3,286	55
March 2016 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	6,362	439
September 2016 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	28,765	3,196
June 2017 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	83,463	11,736
June 2017 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	6,348	845
October 2017 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	129,299	23,772
October 2017 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	$ 11,288	$ 1,674

Warrants (Schedule Of Assumptio

Warrants (Schedule Of Assumptions Used In Calculating Fair Value Of Warrants) (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Trading market prices	$ 2.84	$ 1.91
Estimated future volatility	134.00%	102.00%
Dividend
Equivalent risk-free rate	0.16%
Fundamental transaction likelihood	90.00%	50.00%
Fundamental transaction timing	2020-09	2020-04
Minimum [Member]
Class of Warrant or Right [Line Items]
Estimated future risk-free rate	0.17%	1.57%
Equivalent volatility	92.00%	85.00%
Equivalent risk-free rate		1.57%
Maximum [Member]
Class of Warrant or Right [Line Items]
Estimated future risk-free rate	0.21%	1.72%
Equivalent volatility	103.00%	94.00%
Equivalent risk-free rate		1.59%

Warrants (Schedule Of Unrealize

Warrants (Schedule Of Unrealized Gain/(Loss) On Fair Value Of Warrants) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	$ (168,702)	$ 427,483	$ (227,094)	$ 1,940,854
November 2015 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(2,315)	27,069	(3,231)	224,153
November 2015 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants		55		435
March 2016 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(5,122)	32,874	(5,923)	147,673
September 2016 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(14,126)	72,213	(25,569)	290,082
June 2017 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(53,099)	129,559	(71,727)	517,950
June 2017 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(3,774)	14,553	(5,503)	56,464
October 2017 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(83,121)	135,125	(105,527)	631,626
October 2017 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	$ (7,145)	$ 16,035	$ (9,614)	$ 72,471

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Provision for Income Taxes
Operating loss carry-forward	$ 160,154,000		160,154,000		$ 156,586,000
Federal And State [Member]
Operating Loss Carryforwards [Line Items]
Provision for Income Taxes			$ 0	$ 0

Income Taxes (Schedule Of Defer

Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Income Taxes [Abstract]
Net Operating Loss Carryforwards	$ 44,843,000	$ 43,844,000
Stock Compensation Expense	540,000	1,191,000
Book Tax Differences on Assets and Liabilities	227,000	464,000
Valuation Allowance	(45,610,000)	(45,499,000)
Net Deferred Tax Assets

Commitments And Contingencies (

Commitments And Contingencies (Details) - USD ($)	Jun. 22, 2009	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Feb. 05, 2018
Commitments And Contingencies [Line Items]
Estimated cost to complete contracts		$ 210,000		$ 210,000
One-time milestone payment	$ 1,000,000
Employer matching contribution				100.00%
Maximum percentage of employee's gross pay				3.00%
Employer matching contribution on deferral				50.00%
Percentage of employee's gross pay				2.00%
Expense related to matching contribution		$ 9,785	$ 18,506	$ 21,014	$ 46,385
Percentage of licensing revenue						50.00%
Maximum [Member]
Commitments And Contingencies [Line Items]
Contract term, months				36 months
Licensing revenue agreement						$ 5,000,000
Minimum [Member]
Commitments And Contingencies [Line Items]
Contract term, months				2 months

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details)	Jun. 30, 2020USD ($)
Fair Value Measurements [Abstract]
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	$ 0
Fair Value, Assets, Level 2 to Level 1 Transfers, Amount	0
Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount	0
Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount	$ 0

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:		$ 2,997,220
Warrant Liabilities	$ 268,811	41,717
Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:		999,820
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:		1,997,400
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liabilities
Level 1 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:		2,997,220
Warrant Liabilities
Level 2 [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:		999,820
Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:		1,997,400
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liabilities	$ 268,811	41,717
Level 3 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation Of Changes In The Fair Value Of Liabilities) (Details) - Warrant Liabilities [Member]	6 Months Ended
	Jun. 30, 2020USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 41,717
Unrealized losses, net	227,094
Balance	$ 268,811

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event [Member]	Aug. 03, 2020shares
Subsequent Event [Line Items]
Common stock	215,000
October 2018 [Member]
Subsequent Event [Line Items]
Warrants	160,257
January 2019 [Member]
Subsequent Event [Line Items]
Warrants	208,334